[insert compound of Formula I] This invention relates to novel substituted azaindoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing selective inhibitory activity of oncogenic B-RafV600E protein kinase.
Synthesis and structural assignment of two major metabolites of the LTA4H inhibitor DG-051
作者:Livia A. Enache、Jun Zhang、David W. Sullins、Isaac Kennedy、Emmanuel Onua、David E. Zembower、Frank W. Muellner、Jasbir Singh、Alex S. Kiselyov
DOI:10.1016/j.bmcl.2009.09.097
日期:2009.11
The same twomajor CYP mediated metabolites of DG-051 were produced in the presence of rat, dog, monkey and human liver microsomes. Their respective structures were hypothesized based on mass spectrometry data correlated with the parent structure and confirmed by comparison with authentic synthetic samples. The number of regioisomers synthesized as candidates for metabolite M1 was narrowed down using